Printer Friendly

DISEASE DETECTION INTERNATIONAL, INC., SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT FOR SEVEN-MINUTE AIDS TEST FOR ARGENTINA

 IRVINE, Calif., Nov. 9 /PRNewswire/ -- Disease Detection International, Inc. ("DOTS") (OTC Bulletin Board), announced today the company has signed a three-year exclusive distribution agreement with Bio-Diagnostica, Inc., of Miami, for the sale of the company's SeroCard(R) HIV-1 test kits in Argentina. The company has received a first order for 40,000 of the seven-minute, whole blood, rapid tests used to detect the presence of antibodies to the AIDS virus and expects to begin shipments of 25,000 tests per month during 1994.
 H. Thad Morris, president and CEO of DDI, commented on the agreement: "We are delighted to be working with Bio-Diagnostica in the distribution of our products in Argentina. The Miami-based company is an experienced marketer of numerous medical products and equipment throughout South America via its ownership of local medical diagnostic companies. During the three-year distribution agreement we expect to ship more than 1,500,000 tests for sale in Argentina." Negotiations for distribution rights in other Central and South American countries are pending between the two medical firms.
 DDI's director of distribution for South America, Tony Blanco, stated, "The Argentina agreement represents a significant milestone in the company's strategy of market penetration in Central and South America. The use of the SeroCard HIV-1 test is ideal in medical settings where the availability of sophisticated instrumentation and trained personnel is limited."
 The SeroCard seven-minute format is a unique and patented testing device smaller than a conventional credit card, which allows for a significant savings in the screening of individuals by the use of a single drop of blood obtained from a finger prick, rather than other more complex and costly procedures requiring serum specimens obtained from a venipuncture. No instrumentation is required to obtain an accurate test result and in numerous clinical trials around the world, the test has proven to be greater than 99 percent accurate in identifying infected individuals.
 Disease Detection International, Inc., develops, manufactures and markets a family of patented, rapid diagnostic tests for infectious and sexually transmitted diseases and for the detection of pregnancy and fertility.
 -0- 11/9/93
 /CONTACT: Tom Dean or Luis Mejia of Innovative Research Associates, 212-421-2543/


CO: Disease Detection International, Inc.; Bio-Diagnostica, Inc. ST: California, Florida IN: MTC SU:

GK-TW -- NY014 -- 2132 11/09/93 09:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 9, 1993
Words:380
Previous Article:ESTEE LAUDER COMPANIES IN POLAND FOR THE FIRST TIME
Next Article:MOTOROLA, NEXTEL AGREE TO SALE OF SMR FREQUENCIES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters